

24sure

pre-implantation chromosomal aneuploidy screening

the technical development of single cell analysis technology



- BlueGnome is
 - Dedicated solely to production of clinical microarray solutions
 - Europe's largest manufacturer of clinical microarrays
 - 100+ labs/20+ countries

Introduction to BlueGnome





24sure - aims of test



- To improve fertility rates for IVF
 - Aneuploidy screen for whole chromosomes / arms / large structural changes
 - Single cells (polar bodies, blastomere), multiple cells (trophoectodermal)
- Test characteristics
 - Easily interpretable no CNP / no trait analysis / no ethically questionable results (late onset disorders, cancer predisposition, small CNV/*de novo* imbalances of unknown significance)
 - Rapid (12-24 hours)
 - Low cost per sample / start up investment



24sure BAC microarray

- 3226 BAC Clones chosen (duplicate) and optimized according to performance on over 10000 patients in a post-natal context.
- Clones designed to minimise CNP detection using BlueGnome customer in-house data of +2000 post-natal aCGH cases.

24sure – protocol



- Amplification SurePlex (Rubicon Genomics technology)
- Labelling BlueGnome Fluorescence labelling kit
- Arrays 24sure
- Analysis software BlueFuse Multi



24sure - Protocol timings



Which amplification technology?

Initial testing of BAC arrays focused on amplification technology using control cell samples

- Qiagen Repli-G
- •GE Healthcare GenomiPhi
 - •Sigma WGA4

Qiagen Repli-G

Repli-G





- •Hybridisations showed high noise levels
- •Fast, cost effective, easy to use

• Difficult to QC for specific amplification after simple (gel) QC since negative controls amplified as well as positive controls.

Genomiphi V2



- Wave like patterns make interpretation challenging
- Easy to QC via gel

Sigma WGA4 - GenomePlex

Trisomy 13 – GenomePlex - single cell known abnormality







Single cell +12, -14



24sure - QC checkpoint - amplification



- Cells 1, 2, 3, 4, 6 successfully amplified
- Cell 5 failed to amplify
- Negative control (water) correctly failed to amplify
- Positive controls (100 pg female genomic DNA) amplified successfully
- All amplifications labelled and hybridised

Sigma WGA4 GenomePlex



- Easy to QC
- Low noise
- Long protocol
- High ADO
- Confirmation of aneuploidy with other technologies (FISH, markers, Karyomapping, single cells of cell lines of known abnormality)

Sigma WGA4 – GenomePlex Polar body samples

euploid







aneuploid









24sure - Polar body samples

Tatal as a sector due along la selia s	250
lotal consented polar bodies	250
Successful amplification and hybridisation	209 (84%)
Number of cases	32
Average number of polar bodies per case	8
Euploid results reported for cells	38%
Percentage cases with one or more euploid cells - 75%	
Aneuploid results reported for cells Percentage cases where all cells were aneuploid - 19%	
Successful hybridizations per amplified product	94%

Sigma WGA4 – GenomePlex Blastomere samples

Blastomere amplification B: female, +18 +X - confirmation with STS





Single cell showing Trisomy chr12, duplication ~25Mb chrXq



Sigma WGA4 – GenomePlex whole embryo/trophoblastic samples 4-20 cells

Multiple cell biopsy





Multiple cell biopsy





BlueGnome 24sure using SurePlex amplification



15pg Sureplex female sample – top array Promega DNA / bottom array SurePlex amplified control DNA







SurePlex - Blastomere single cell sample





SurePlex - Blastomere single cell sample





SurePlex - Blastomere single sample









- Easy to QC
- Low noise
- Short protocol
- Low ADO suitable for genotyping





Results courtesy of Rubicon Genomics



ADO of SurePlex

	10 ng DNA	5 cells	single cell
drop out rate*	10%	13%	11%
avg. standard deviation of 48 assays**	-	-	1.6 cycles
ave. standard deviation of top 24 assays***	-	-	0.6 cycles

Results courtesy of Rubicon Genomics





•24sure has been used to reliably identify aneuploidy in single/multiple cells

•24sure technology has been validated with a wide range of amplification protocols

•SurePlex amplification technology has been found to be most suitable for 24sure

•Clinical efficacy unknown

•Robust clinical studies are required



24sure

pre-implantation chromosomal aneuploidy screening